Piper Jaffray Reiterates Overweight Rating On NuVasive

In a report published by Piper Jaffray, NuVasive NUVA Overweight rating is reiterated.

Piper Jaffray said that it travelled with management for a series of investor meetings yesterday and came away with some fresh insights on the company and its prospects. “While a number of questions and controversies face the company and the spine market more broadly, there are also catalysts on deck that could begin to drive the stock off its current levels of relatively depressed valuation. We remain bullish the stock, we reiterate our Overweight rating, and continue to recommend the stock for investors able to tolerate potential near- and intermediate-term volatility related to the spine market.”

NuVasive closed yesterday at $26.80.